Scarica l'app Stockscreener
30.63
4.18%
1.23
Dopo l'orario di chiusura:
31.90
1.27
+4.15%
Precedente Chiudi:
$29.40
Aprire:
$28.42
Volume 24 ore:
2.25M
Relative Volume:
4.62
Capitalizzazione di mercato:
$2.22B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-11.18
EPS:
-2.74
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
-8.70%
1M Prestazione:
-16.08%
6M Prestazione:
-24.54%
1 anno Prestazione:
-27.50%
Intervallo 1D:
$27.56
$31.52
Intervallo di 1 settimana:
$27.56
$33.64
Portata 52W:
$27.56
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Confronta XENE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
30.63 | 2.22B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com - Defense World
JPMorgan Chase & Co. Increases Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Prudential Financial Inc. Acquires 24,956 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Raymond James Financial Inc. Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data (NASDAQ:XENE) - Seeking Alpha
Xenon Slides Ahead of San Diego Concference - Baystreet.ca
Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025 - TipRanks
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 - The Manila Times
Breakthrough Epilepsy Drug Shows Remarkable 3-Year Efficacy Data - Stock Titan
Investors Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Enters Oversold Territory (XENE) - Nasdaq
Thrivent Financial for Lutherans Sells 12,394 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Teacher Retirement System of Texas Acquires 2,994 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Hold - Defense World
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Swiss National Bank - Defense World
(XENE) Trading Advice - news.stocktradersdaily.com
Xenon Pharmaceuticals announces executive changes - MSN
Bank of New York Mellon Corp Sells 2,294 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
What is William Blair’s Estimate for XENE Q1 Earnings? - The AM Reporter
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals at Stifel Forum: Strategic Advances in CNS By Investing.com - Investing.com Canada
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role - MSN
(XENE) Trading Signals - Stock Traders Daily
Xenon Pharmaceuticals to Present at Stifel 2025 Virtual CNS Forum - TipRanks
Xenon to Present at Stifel 2025 Virtual CNS Forum - The Manila Times
Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of “Buy” by Brokerages - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals appoints PwC as new auditor - Investing.com
Xenon Pharmaceuticals appoints PwC as new auditor By Investing.com - Investing.com South Africa
New KCNQ2/3 activators disclosed in Xenon Pharmaceuticals patents - BioWorld Online
Q1 Earnings Forecast for XENE Issued By HC Wainwright - Defense World
Equities Analysts Offer Predictions for XENE Q1 Earnings - Defense World
(XENE) On The My Stocks Page - Stock Traders Daily
What is Leerink Partnrs’ Estimate for XENE Q1 Earnings? - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 1-Year Low – Time to Sell? - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Earns “Outperform” Rating from William Blair - Defense World
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
HC Wainwright Has Pessimistic Outlook of XENE Q1 Earnings - MarketBeat
Strategic Growth Potential and Upcoming Catalysts Drive Buy Rating for Xenon Pharmaceuticals - TipRanks
Xenon Pharmaceuticals price target lowered to $42 from $43 at Wedbush - TipRanks
Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
RBC Capital Adjusts Xenon Pharmaceuticals Price Target to $58 From $56, Maintains OutperformSpeculative Risk Rating - MarketScreener
Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $60 From $67, Maintains Buy Rating - Marketscreener.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Call Transcript - Insider Monkey
Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):